Arabic Arabic English English French French German German
dark

Public Meeting: Patient-Focused Drug Development for Hemophilia A, B, & Other Bleeding Disorders 1

On September 22, 2014, FDA hosted a public meeting on Patient-Focused Drug Development for Hemophilia A, B, and Other Heritable Bleeding Disorders. FDA was interested in obtaining patient perspectives on the impact of Hemophilia A, B, and Other Heritable Bleeding Disorders on daily life and patient views on treatment approaches. For more information, visit the meeting webpage. https://www.fda.gov/industry/prescription-drug-user-fee-amendments/fda-led-patient-focused-drug-development-pfdd-public-meetings#hemophilia

Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Public Meeting: Patient-Focused Drug Development for Hemophilia A, B, & Other Bleeding Disorders 2

Next Post

The work here provides novel experimental evidence supporting the notion that Rb1 protects against cardiac hypertrophy.

Related Posts
Total
0
Share